Patient With COPD-Asthma Overlap Detected by Sputum Eosinophilia

Glenda Ernsta, c, Bethy Camargob, Eduardo Borsinia, Martin Bosioa, Alejandro Iottia, Alejandro Salvadoa

Abstract

A 70-year-old man was diagnosed with COPD. He reported symptoms of nocturnal shortness of breath, cough and wheezing in the last time; however, he had never had asthma. Despite the treatment and the pulmonary rehabilitation, our patient referred the persistence of the symptoms. In a research screening of differential cellular count in the induced sputum in patients with COPD, we found that his sample showed high percentage of eosinophils. Due to this finding, we started to study him. Peripheral eosinophilia, FeNO and IgE were also found to be elevated. In the last years, he had chronic rhinitis. Besides, the reversibility of lung function after bronchodilators was observed. The algorithms to diagnose asthma-COPD overlap syndrome (ACOS) include positive bronchodilator response, sputum eosinophilia or previous diagnosis of asthma, high IgE and/or history of atopy. Our patient was diagnosed with ACOS, and the sputum findings have contributed to the modification of his treatment and lead to a clinical improvement and reduction of the symptoms.

Keywords: Asthma-COPD overlap; Eosinophils; Sputum sample

Introduction

Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have defined the asthma-COPD overlap syndrome (ACOS) as an illness characterized by persistent airflow limitation with several features associated with asthma and others associated with COPD [1]. However, the heterogeneity of the airway inflammation is present in asthma-COPD overlap, therefore ACOS could present different phenotypes defined by eosinophilic or neutrophilic pattern [2]. It has been previously described that asthma-COPD overlap has prevalence of around 2% of adult population or 20% of COPD patients [3].

Diagnosis of ACOS is important because patients with ACOS have more exacerbations and they are more severe than subjects with either asthma or COPD alone [4].

We presented a COPD patient, without history of asthma, which was diagnosed with ACOS due to high eosinophilia in sputum. The proper diagnosis has contributed to the modification of the standard treatment, leading to a clinical improvement in this patient.

Case Report

The patient is a 70-year-old man with a body mass index of 24.9 and smoking history (116 pack/year). He was diagnosed with COPD (GOLD-1) and emphysema (Fig. 1). He presented dyspnea (mMRCII), low diffusion capacity of carbon monoxide (DLCO: 29%) (Table 1), 6-min walking test with 352 m walked and desaturation (94-90%, Borg: 0-1). The patient started pulmonary rehabilitation twice a week.

He had a right pneumonia and empyema in 2009, which was treated with thoracic drainage, showing PPD and pleural effusion culture negatives with normal pleural biopsy. Since 2013, he is having chronic rhinitis treated with aqueous mometasone spray.

Despite the COPD treatment with budesonide, formoterol, glycopyrronium, indacaterol and ipratropium nebulized, he reported symptoms of nocturnal shortness of breath, cough and wheezing in the last 2 years. He had never had asthma symptoms.

In the screening study, the induced sputum sample was performed according to the criteria previously described [5]. A rise in percentage of the sputum eosinophilia was found (Fig. 2). Differential sputum count showed 12.8% macrophages, 49.7% neutrophils, 35% eosinophils, 0% lymphocytes and 2.5% epithelial cells. These findings contributed to the support of ACOS as diagnosis, and then additional studies were performed. Peripheral eosinophilia (11%, 990 mm3) was also found with the rest of parameters in a normal range. The patient showed FeNO of 120 ppb and IgE of 248 UI. Other diagnoses associated with eosinophilia such as parasitosis, allergic bronchopulmonary aspergillosis or Churg-Strauss syndrome were discarded.

Owing to these findings like eosinophilia, reversibility...
of airflow, increased levels of FeNO and IgE, we decided to change the treatment. The patient began to receive glycopyrrolonium, indacaterol and mometasone (800 µg using inhaled capsule during 2 weeks and then he began to use 400 µg). Six weeks later, the patient underwent a control. Decreases in the level of FeNO (40 ppb) and in the percentage of sputum eosinophils (7.6%) were observed. Moreover, at the clinical examination, he did not show wheezing, and he referred an improvement of the nocturnal symptoms. Currently, this patient follows with this pharmacological therapy and he remains clinically stable.

Discussion

It was previously described that a subgroup of COPD patients required treatment with inhaled corticosteroids (ICS)/long-acting beta agonist (LABA) in order to improve the long-term management for the illnesses [6].

ACOS has been identified by the features that it shares with both asthma and COPD. These include COPD patients with emphysema and partially reversible airflow obstruction, with or without environmental allergies, reduced DLCO and/or sputum eosinophilia and asthma patients who present partially reversible airflow obstruction with or without emphysema or DLCO < 80% of teoric value [7]. Recently new diagnosis algorithm has been proposed. It included two major or one major and two minor criteria. The major criteria are very positive bronchodilator response (> 400 mL and 15% in FEV1), sputum eosinophilia or previous diagnosis of asthma. The minor criteria are high IgE, previous history of atopy or positive bronchodilator test (> 200 mL and 12% in FEV1) in at least two opportunities [8].

Asthma-COPD overlap leads to health status impairment, increased exacerbations, hospitalizations and mortality. Moreover, in young patients (20 - 44 years old) with ACOS, the diagnosis of ACOS was associated with an increase of the hospitalization rate and the number of hospital admissions compared with severe asthma population [9].

The relevance of recognizing the ACOS in patients with COPD, who have eosinophilic inflammation, is the change of habitual treatment. It has been found that these patients

<table>
<thead>
<tr>
<th>L</th>
<th>Percentages</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1 pre</td>
<td>2.11</td>
</tr>
<tr>
<td>FEV1 post</td>
<td>2.34</td>
</tr>
<tr>
<td>FVC pre</td>
<td>4.09</td>
</tr>
<tr>
<td>FVC post</td>
<td>4.09</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>51</td>
</tr>
<tr>
<td>DLCO</td>
<td>29</td>
</tr>
<tr>
<td>DLCO corrected</td>
<td>29</td>
</tr>
</tbody>
</table>
presented improvement in FEV1 after receiving ICS, which suggested that sputum eosinophilia could be a predictor of response of corticosteroids.

The induced sputum is a non-invasive processing. A sensitivity of 82.4% and a specificity of 84.8% of eosinophilia sputum have been reported for detection of asthma-COPD overlap, using a cut-off value of 2.5% [10].

Although induced sputum cell count is a non-invasive technique, it is not usually performed to study COPD patients. Nevertheless, in our patient, the eosinophilic pattern in the sputum sample contributed to the recognition of the ACOS.

Acknowledgement

We are especially grateful to Dr. Alvar Agusti (Hospital Clinic, University of Barcelona, Barcelona, Spain) by reading and correcting the manuscript with such dedication.

Conflict of Interest

The authors have not conflict of interest to declare.

Grant

This work was supported by grant from ROEMMERS Foundation.

References